Improved HIV-Adenoviral Vector Vaccine for Re-immunization

用于再免疫的改良 HIV 腺病毒载体疫苗

基本信息

  • 批准号:
    7166854
  • 负责人:
  • 金额:
    $ 30.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-08-01 至 2008-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The objective of this project is to develop an adenoviral vector vaccine against HIV that is effective in stimulating cell-mediated immunity in animals previously immune to adenovirus The HIV vaccine will be used to protect against infection and to treat the infected. Gag, Pol, and Nef are HIV proteins that have been reported to be useful for vaccine development. Evidence indicates that a broad cell-mediated immune (CMI) response is needed to treat or prevent HIV infection. Adenovirus (Ad) vector vaccines induce CMI responses and have emerged as a leading candidate to be used as a vaccine delivery platform. First Generation Ad vaccines have proven less effective than anticipated and adverse reactions are in question. Furthermore, pre-existing Ad immunity of most humans causes decreased effectiveness. To address these issues, we have developed an advanced Ad based vector that is devoid of early genes E1, E3, and E2B. "E2B-deleted" vectors, with deletions in the polymerase and preterminal protein genes, have an expanded cloning capacity and greatly reduced expression of viral late genes as compared to First Generation Ad vectors. Reduced expression of multiple Ad viral genes is advantageous for vaccine development for reasons such as reduced antigenic competition, greater longevity of expression that provides greater immunologic stimulus and reduced adverse effects. Such advantages are important in the presence of pre-existing Ad immunity since the Ad vector needs to be stealth-like. The Company has exclusive license from the U of M for the new Ad vector system and the E.C7 cell line, which supports vector production. The proposed vaccines based on the new E2B-deleted Ad vector system will carry fused Ad-gag-pol, fused Ad-gag-pol-nef and Clade C env genes. The HIV vaccines will be tested for their potential to induce CMI as a prime and for their re-immunization (boost) potential in Ad-naive and Ad-immune mice. Upon completion of this project, we will have developed a new platform for the delivery of HIV vaccines that is effective, safe, stable, cost effective, easy to distribute and use. Our goal is to initiate non-human primate studies in the Phase II SBIR and a Phase I clinical trial using these or like vaccine product within 2 to 3 years of funding as pre-clinical data allows.
描述(由申请人提供):本项目的目的是开发一种抗HIV的腺病毒载体疫苗,该疫苗可有效刺激先前对腺病毒免疫的动物的细胞介导的免疫力。HIV疫苗将用于预防感染和治疗感染者。Gag、Pol和Nef是已报道可用于疫苗开发的HIV蛋白。有证据表明,需要广泛的细胞介导的免疫(CMI)反应来治疗或预防HIV感染。腺病毒(Ad)载体疫苗诱导CMI应答,并且已经成为用作疫苗递送平台的主要候选者。第一代Ad疫苗已被证明不如预期有效,不良反应也存在疑问。此外,大多数人预先存在的Ad免疫力导致有效性降低。为了解决这些问题,我们开发了一种先进的基于Ad的载体,其缺乏早期基因E1、E3和E2 B。与第一代Ad载体相比,在聚合酶和前末端蛋白基因中具有缺失的“E2 B缺失”载体具有扩大的克隆能力和大大降低的病毒晚期基因表达。多个Ad病毒基因的表达减少有利于疫苗开发,原因是例如抗原竞争减少、提供更大免疫刺激的更长的表达寿命和减少的副作用。这样的优点在预先存在的Ad免疫力的存在下是重要的,因为Ad载体需要是隐形的。该公司已从密歇根大学独家许可的新的广告载体系统和E.C7细胞系,支持载体生产。基于新的E2 B缺失的Ad载体系统的所提出的疫苗将携带融合的Ad-gag-pol、融合的Ad-gag-pol-nef和进化枝C env基因。将检测HIV疫苗诱导CMI作为初免的潜力以及在Ad-未处理和Ad-免疫小鼠中再次免疫(加强)的潜力。该项目完成后,我们将开发一个新的艾滋病毒疫苗交付平台,该平台有效、安全、稳定、成本效益高、易于分发和使用。我们的目标是在临床前数据允许的情况下,在2至3年的资助期内,在II期SBIR和I期临床试验中使用这些或类似疫苗产品启动非人灵长类动物研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard B. Gayle其他文献

Inhibition de l'activation et du recrutement des plaquettes
抑制血小板的激活和再生
  • DOI:
  • 发表时间:
    1999
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Charles R. Maliszewski;Richard B. Gayle;Aaron J. Marcus
  • 通讯作者:
    Aaron J. Marcus

Richard B. Gayle的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard B. Gayle', 18)}}的其他基金

ANALYSIS OF GENETIC DATA USING BIOCONDUCTOR R
使用 BIOCONDUCTOR R 分析遗传数据
  • 批准号:
    7610322
  • 财政年份:
    2007
  • 资助金额:
    $ 30.85万
  • 项目类别:
Improved HIV-Adenoviral Vector Vaccine for Re-immunization
用于再免疫的改良 HIV 腺病毒载体疫苗
  • 批准号:
    7265276
  • 财政年份:
    2006
  • 资助金额:
    $ 30.85万
  • 项目类别:
STATISTICAL CONSULTATION AND BIOINFORMATICS
统计咨询和生物信息学
  • 批准号:
    7381717
  • 财政年份:
    2006
  • 资助金额:
    $ 30.85万
  • 项目类别:
STATISTICAL CONSULTATION AND BIOINFORMATICS
统计咨询和生物信息学
  • 批准号:
    7170941
  • 财政年份:
    2005
  • 资助金额:
    $ 30.85万
  • 项目类别:

相似海外基金

DIRECT ADMIN /ADENOVIRIDAE VECTOR W/VEGF121/ CDNA TO LOWER ISCHEMIC LIMB
直接管理/腺病毒载体 W/VEGF121/ CDNA 至下肢缺血
  • 批准号:
    6304094
  • 财政年份:
    1999
  • 资助金额:
    $ 30.85万
  • 项目类别:
DIRECT ADMIN /ADENOVIRIDAE VECTOR W/VEGF121/ CDNA TO LOWER ISCHEMIC LIMB
直接管理/腺病毒载体 W/VEGF121/ CDNA 至下肢缺血
  • 批准号:
    6263933
  • 财政年份:
    1998
  • 资助金额:
    $ 30.85万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了